Indication evaluation and prioritization for development stage pharmaceutical client

Client Problems

• A privately-held, development stage pharmaceutical company wanted to understand the clinical and commercial factors across a breadth of indications in order to prioritize development

• There were initial thoughts on several broad disease areas, but no concrete goal or therapeutic target

What We Did

• Started with a narrow selection of indication in the first round of study, and then expanded into a total of 12 indications (grouped into three broad categories) to assess the full potential breadth of the market

Our Results And Insight

• Indications were evaluated along commercial, technical, and clinical dimensions.

• Within these dimensions, scores were assigned across 14 sub-categories, and summed to represent total opportunity

• Based on these scores and other factors, indications were ranked from highest to lowest opportunity

Service Areas Details

Commercial Strategy (Indication Prioritization)

Therapeutic Areas Details

Gene Therapy & Orphan Disease